ArticleFrontiers in immunology2025
Integration of single-cell RNA and bulk RNA sequencing revealed malignant ductal cell heterogeneity and prognosis signatures in pancreatic cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Improving pancreatic adenocarcinoma prognosis models through ligand receptor interactions and histopathological integration.Journal of translational medicine · 2026Article
- Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).Molecular medicine reports · 2026Review
- Klf4-Tymp axis promotes inflammation-driven early tumorigenesis by enhancing kras mutation-induced acinar-to-ductal metaplasia through Pi3k/Akt and Mek/Erk pathways.Journal of experimental & clinical cancer research : CR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pancreatic cancer is a highly malignant tumor of the digestive system with a dismal prognosis. Despite advances in diagnosis and treatment, overall survival remains extremely low. Early diagnostic markers and an improved understanding of tumor-microenvironment interactions are essential for developing more effective therapies. Methods: We analyzed 74 single-cell RNA sequencing (scRNA-seq) samples, performing unsupervised clustering and marker-gene expression profiling to define major cell types. Large-scale chromosomal copy-number variation (CNV) analysis distinguished malignant from non-malignant ductal cells. Non-negative matrix factorization (NMF) identified stage-associated gene modules, which were integrated with TCGA bulk-RNA data and machine-learning feature selection to pinpoint candidate prognostic genes. Two independent cohorts were used for validation. Regulatory network inference (pySCENIC) and ligand-receptor interaction analysis (CellPhoneDB) explored cross-talk between malignant cells and macrophages. Finally, in vitro knockdown of CTSV assessed its functional role in pancreatic cancer (PAC) cell proliferation and migration. Results: Three prognosis-related genes-ANLN, NT5E, and CTSV-were selected based on their strong association with clinical stage and validated in external datasets. High expression of these genes correlated with poorer overall survival and an increased infiltration of M0 macrophages. CellPhoneDB predicted significant interactions between high-expression malignant ductal cells and M0 macrophages via CXCL14-CXCR4 and IL1RAP-PTPRF axes, with SPI1 identified as an upstream regulator of IL1RAP. In vitro CTSV knockdown significantly inhibited PAC cell proliferation and migration. Discussion: Our integrative single-cell and bulk-RNA workflow identifies ANLN, NT5E, and CTSV as novel prognostic biomarkers in pancreatic cancer and highlights a pro-tumorigenic interaction between malignant ductal cells and macrophages. Targeting CTSV or disrupting CXCL14-CXCR4 and IL1RAP-PTPRF signaling may offer new therapeutic avenues for PAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.